Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New web app aims to help sickle cell patients plan healthy families

NCT ID NCT05292781

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a web-based tool called CHOICES that provides tailored information about reproductive health options for people with sickle cell disease or trait. The study involves 506 adults aged 18-45 who plan to have a child within two years. The goal is to see if the tool improves their knowledge about genetic transmission, parenting options, and safe contraception.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CHOICES web application
What this could lead to
If successful, this tool could help people with sickle cell disease or trait make informed decisions about having children without sickle cell disease.
What could go wrong
This is a behavioral intervention study, not a medical treatment. The main outcome is knowledge, not actual health improvement, so real-world impact may be limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 506 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of SCD (HbSS, HbSC (Hemoglobin Sickle C Disease), HbS-beta-0 thalassemia, and HbS-beta+ thalassemia) or report of SCT (SCD is Hgb electrophoresis confirmed; SCT evaluated by SickleScan); * Able and intends to conceive a child in the next 2 years (first child or another child); * Speaks and reads English; * 18 to 45 years; * At-risk for having a child with SCD (i.e., sexual/ reproductive partner has SCD, SCT, or unknown sickle cell status); and * Wants to avoid the risk of a child with SCD. * The age range is based on typical reproductive age for SCD where median survival is 42 years for men and 48 years for women. Exclusion Criteria: * Legally blind; * Physically unable to complete the study questionnaires or the intervention; * Report health history of hysterectomy, tubal ligation, medically or surgically induced menopause, or vasectomy that would * Prevent ability to bear children; * Report a desire to remain childless or have no further children; * Report knowing or being a relative or friend of a participant previously enrolled in the study, or * Previous participation in a CHOICES study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sickle cell disease Sickle Cell Trait

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sickle cell disease Sickle cell trait

Contacts and locations

Locations

  • University of Florida

    Gainesville, Florida, 32611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.